SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- 5 Top Tips for Colonoscopy (GI & Endoscopy News)
- Scientists uncover gut signals that may improve early cancer detection (Earth.com)
- The AGA Research Foundation awards $2.9 million in digestive health research funding (EurekAlert!)
- The GI hospitalist: A practice-changing health care opportunity (MDedge)
- Virtual Multidisciplinary GI Care Improves Outcomes, Reduces Costs (Gastroenterology Advisor)
- Validation of the American Society for Gastrointestinal Endoscopy’s Complexity Grading System for Endoscopic Procedures (Clinical and Translational Gastroenterology )
- A Randomized Trial of Rifaximin vs Low FODMAP Diet for Symptom Outcomes and Microbiome Changes in Irritable Bowel Syndrome (Clinical GI & Hepatology)
- Aspirin Unlikely to Cut Colorectal Cancer Incidence (Medscape)
